Skip to main content
Clinical Trials/NCT02430584
NCT02430584UnknownNot Applicable

Whole Blood Specimen Collection From Pregnant Subjects

Progenity, Inc.1 site in 1 country5,000 target enrollmentStarted: March 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
5,000
Locations
1
Primary Endpoint
Whole blood collection

Study Overview

Brief Summary

To obtain whole blood specimens from pregnant subjects to be used for research and development and clinical validation studies of prenatal assays.

Detailed Description

This sample collection protocol allows for the identification, recruitment, and participation in women who are pregnant and are known to:

  1. be at an increased risk for fetal genetic abnormalities
  2. be at increased risk for congenital fetal infection by virtue of being positive by initial screening tests, or are known to have an active infection during this pregnancy.
  3. possess irregular blood group antigens (the subject or the father of the baby) and are therefore at increased risk for fetal sensitization during this pregnancy.

Study Design

Study Type
Observational
Observational Model
Family Based
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Subject willing to provide consent to have up to 50 mL of whole blood collected at one or more monthly (≥25 days) clinic visits
  • Subject is pregnant carrying a singleton fetus of 10 to 26 weeks gestational age inclusive
  • Subject is 18 years of age or older
  • Subject is at an increased risk for one or more of the following:
  • fetal gene and chromosome abnormalities
  • congenital fetal infection
  • known to possess irregular blood group antigens (subject or father of the baby)
  • known to have some other condition amenable to noninvasive prenatal testing

Exclusion Criteria

  • Pregnancy is non-viable

Outcomes

Primary Outcomes

Whole blood collection

Time Frame: One or more monthly clinic visits (≥25 days apart) over 13 weeks

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials